Halozyme Therapeutics, Inc. (0J2O.L)
USD 56.78
(-5.49%)
USD 56.78
(-5.49%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.73 Billion USD | -5.88% |
| 2022 | 1.84 Billion USD | 66.74% |
| 2021 | 1.1 Billion USD | 90.44% |
| 2020 | 579.92 Million USD | 2.48% |
| 2019 | 565.87 Million USD | 28.54% |
| 2018 | 440.24 Million USD | -15.33% |
| 2017 | 519.94 Million USD | 98.82% |
| 2016 | 261.51 Million USD | 43.86% |
| 2015 | 181.78 Million USD | 9.53% |
| 2014 | 165.97 Million USD | 63.05% |
| 2013 | 101.79 Million USD | -24.45% |
| 2012 | 134.72 Million USD | 104.88% |
| 2011 | 65.75 Million USD | -28.01% |
| 2010 | 91.34 Million USD | 18.4% |
| 2009 | 77.14 Million USD | 0.77% |
| 2008 | 76.56 Million USD | -26.0% |
| 2007 | 103.46 Million USD | 124.47% |
| 2006 | 46.09 Million USD | 124.72% |
| 2005 | 20.51 Million USD | 25.03% |
| 2004 | 16.4 Million USD | 34421.69% |
| 2003 | 47.51 Thousand USD | -51.14% |
| 2002 | 97.24 Thousand USD | 272.22% |
| 2001 | 26.12 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.84 Billion USD | 6.25% |
| 2024 Q2 | 1.96 Billion USD | 6.95% |
| 2024 Q3 | 2.11 Billion USD | 7.54% |
| 2023 Q4 | 1.73 Billion USD | -8.42% |
| 2023 Q2 | 1.81 Billion USD | 6.53% |
| 2023 Q1 | 1.69 Billion USD | -7.71% |
| 2023 Q3 | 1.89 Billion USD | 4.54% |
| 2023 FY | 1.73 Billion USD | -5.88% |
| 2022 FY | 1.84 Billion USD | 66.74% |
| 2022 Q4 | 1.84 Billion USD | -1.24% |
| 2022 Q1 | 1.16 Billion USD | 5.24% |
| 2022 Q2 | 1.78 Billion USD | 53.27% |
| 2022 Q3 | 1.86 Billion USD | 4.67% |
| 2021 Q2 | 1.02 Billion USD | 6.13% |
| 2021 Q1 | 966.58 Million USD | 66.67% |
| 2021 Q4 | 1.1 Billion USD | -6.83% |
| 2021 Q3 | 1.18 Billion USD | 15.55% |
| 2021 FY | 1.1 Billion USD | 90.44% |
| 2020 Q1 | 492.35 Million USD | -12.99% |
| 2020 Q3 | 524.02 Million USD | -0.56% |
| 2020 Q4 | 579.92 Million USD | 10.67% |
| 2020 FY | 579.92 Million USD | 2.48% |
| 2020 Q2 | 526.99 Million USD | 7.04% |
| 2019 Q4 | 565.87 Million USD | 52.79% |
| 2019 FY | 565.87 Million USD | 28.54% |
| 2019 Q3 | 370.35 Million USD | -11.36% |
| 2019 Q2 | 417.83 Million USD | -2.63% |
| 2019 Q1 | 429.1 Million USD | -2.53% |
| 2018 FY | 440.24 Million USD | -15.33% |
| 2018 Q4 | 440.24 Million USD | -0.96% |
| 2018 Q3 | 444.5 Million USD | -6.37% |
| 2018 Q2 | 474.75 Million USD | -4.18% |
| 2018 Q1 | 495.46 Million USD | -4.71% |
| 2017 Q2 | 344.78 Million USD | 52.04% |
| 2017 FY | 519.94 Million USD | 98.82% |
| 2017 Q1 | 226.76 Million USD | -13.29% |
| 2017 Q4 | 519.94 Million USD | 45.58% |
| 2017 Q3 | 357.14 Million USD | 3.59% |
| 2016 Q4 | 261.51 Million USD | -7.43% |
| 2016 FY | 261.51 Million USD | 43.86% |
| 2016 Q2 | 296.12 Million USD | -4.2% |
| 2016 Q1 | 309.09 Million USD | 70.03% |
| 2016 Q3 | 282.49 Million USD | -4.6% |
| 2015 FY | 181.78 Million USD | 9.53% |
| 2015 Q3 | 158.73 Million USD | -8.8% |
| 2015 Q1 | 159.12 Million USD | -4.13% |
| 2015 Q2 | 174.04 Million USD | 9.38% |
| 2015 Q4 | 181.78 Million USD | 14.52% |
| 2014 FY | 165.97 Million USD | 63.05% |
| 2014 Q2 | 182.05 Million USD | -7.91% |
| 2014 Q3 | 164.62 Million USD | -9.57% |
| 2014 Q1 | 197.68 Million USD | 94.21% |
| 2014 Q4 | 165.97 Million USD | 0.82% |
| 2013 Q4 | 101.79 Million USD | -7.58% |
| 2013 Q2 | 107.38 Million USD | -8.11% |
| 2013 Q1 | 116.86 Million USD | -13.26% |
| 2013 FY | 101.79 Million USD | -24.45% |
| 2013 Q3 | 110.14 Million USD | 2.57% |
| 2012 FY | 134.72 Million USD | 104.88% |
| 2012 Q4 | 134.72 Million USD | 24.77% |
| 2012 Q3 | 107.98 Million USD | -11.31% |
| 2012 Q2 | 121.74 Million USD | -9.63% |
| 2012 Q1 | 134.71 Million USD | 104.87% |
| 2011 Q4 | 65.75 Million USD | -15.96% |
| 2011 FY | 65.75 Million USD | -28.01% |
| 2011 Q2 | 89.5 Million USD | 10.6% |
| 2011 Q1 | 80.93 Million USD | -11.4% |
| 2011 Q3 | 78.24 Million USD | -12.59% |
| 2010 Q1 | 65.16 Million USD | -15.54% |
| 2010 Q2 | 51.48 Million USD | -20.99% |
| 2010 Q3 | 100.39 Million USD | 94.99% |
| 2010 FY | 91.34 Million USD | 18.4% |
| 2010 Q4 | 91.34 Million USD | -9.01% |
| 2009 Q2 | 96.29 Million USD | 39.71% |
| 2009 Q3 | 86.1 Million USD | -10.58% |
| 2009 Q4 | 77.14 Million USD | -10.4% |
| 2009 FY | 77.14 Million USD | 0.77% |
| 2009 Q1 | 68.92 Million USD | -9.97% |
| 2008 Q3 | 80.75 Million USD | -8.81% |
| 2008 Q2 | 88.55 Million USD | -10.43% |
| 2008 Q1 | 98.87 Million USD | -4.44% |
| 2008 Q4 | 76.56 Million USD | -5.19% |
| 2008 FY | 76.56 Million USD | -26.0% |
| 2007 Q3 | 109.99 Million USD | 5.63% |
| 2007 Q2 | 104.12 Million USD | 40.97% |
| 2007 Q1 | 73.86 Million USD | 60.26% |
| 2007 FY | 103.46 Million USD | 124.47% |
| 2007 Q4 | 103.46 Million USD | -5.94% |
| 2006 Q4 | 46.09 Million USD | 158.77% |
| 2006 Q2 | 16.84 Million USD | -11.22% |
| 2006 Q3 | 17.81 Million USD | 5.76% |
| 2006 FY | 46.09 Million USD | 124.72% |
| 2006 Q1 | 18.97 Million USD | -7.5% |
| 2005 Q3 | 7.38 Million USD | -32.48% |
| 2005 Q1 | 13.87 Million USD | -15.4% |
| 2005 Q2 | 10.93 Million USD | -21.18% |
| 2005 Q4 | 20.51 Million USD | 177.72% |
| 2005 FY | 20.51 Million USD | 25.03% |
| 2004 Q2 | 6.2 Million USD | -19.71% |
| 2004 Q3 | 3.78 Million USD | -39.03% |
| 2004 FY | 16.4 Million USD | 34421.69% |
| 2004 Q4 | 16.4 Million USD | 333.37% |
| 2004 Q1 | 7.73 Million USD | 16173.7% |
| 2003 Q4 | 47.51 Thousand USD | -30.27% |
| 2003 Q3 | 68.14 Thousand USD | -11.52% |
| 2003 FY | 47.51 Thousand USD | -51.14% |
| 2003 Q1 | 91.97 Thousand USD | -5.43% |
| 2003 Q2 | 77.02 Thousand USD | -16.25% |
| 2002 Q3 | 136.79 Thousand USD | -7.27% |
| 2002 Q1 | 37.86 Thousand USD | 0.0% |
| 2002 Q2 | 147.52 Thousand USD | 289.58% |
| 2002 Q4 | 97.24 Thousand USD | -28.91% |
| 2002 FY | 97.24 Thousand USD | 272.22% |
| 2001 FY | 26.12 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -108.404% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -84.957% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -122.82% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -947.268% |
| bluebird bio, Inc. | 619.16 Million USD | -179.938% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -1277.316% |
| Imunon, Inc. | 21.91 Million USD | -7807.95% |
| Editas Medicine, Inc. | 499.15 Million USD | -247.242% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 93.504% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 48.346% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -44.596% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 46.692% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -23.016% |
| Verastem, Inc. | 149.71 Million USD | -1057.69% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 97.861% |
| Waters Corporation | 4.62 Billion USD | 62.539% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 98.244% |
| Biogen Inc. | 26.84 Billion USD | 93.543% |
| Nektar Therapeutics | 398.03 Million USD | -335.459% |
| Perrigo Company plc | 10.8 Billion USD | 83.965% |
| Dynavax Technologies Corporation | 997.09 Million USD | -73.832% |
| Illumina, Inc. | 10.11 Billion USD | 82.858% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -6030.609% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -122.114% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -678.977% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -2538.56% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 74.666% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -948.433% |
| Evolus, Inc. | 188.99 Million USD | -817.084% |
| Adicet Bio, Inc. | 207.29 Million USD | -736.137% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -778.027% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 94.76% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -742.227% |
| FibroGen, Inc. | 423.52 Million USD | -309.245% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 83.896% |
| OPKO Health, Inc. | 2.01 Billion USD | 13.84% |
| Homology Medicines, Inc. | 47.05 Million USD | -3583.341% |
| Geron Corporation | 394.07 Million USD | -339.831% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 54.743% |
| Exelixis, Inc. | 2.94 Billion USD | 41.092% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -370.371% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -1022.686% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -33.228% |
| Zoetis Inc. | 14.28 Billion USD | 87.867% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -194.656% |
| Abeona Therapeutics Inc. | 64 Million USD | -2608.15% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 92.375% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -2997.946% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 42.032% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 46.907% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -178.877% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -65.191% |
| Insmed Incorporated | 1.32 Billion USD | -30.337% |
| TG Therapeutics, Inc. | 329.58 Million USD | -425.891% |
| Incyte Corporation | 6.78 Billion USD | 74.443% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 5.539% |